MorningSignal
Research Platform
2026-07-23 07:34
type: earnings-brief date: 2026-07-16 session: AM status: call-highlights-complete-q-and-a-provisional universe: US-listed market cap above $2B tags: [earnings, sellside, expectations-gap, thesis-delta]
Authoritative unattended run for morningsignal-am · evidence bundle generated 10:18 PM ET · closing prices from the deterministic collector · active Codex task authored all analysis · no API key or token-backed service used
This was a forward-bar tape, not a headline-beat tape. Abbott (+10.7%), Prologis (+4.6%) and Citizens (+4.6%) were rewarded because their releases improved the forward growth or earnings floor. TSMC (-2.3%) and GE Aerospace (-4.1%) delivered strong operating results but failed to clear valuation-implied expectations: investors focused on TSMC's $60–64 billion capital-intensity burden and GE's 130-basis-point margin compression. UnitedHealth closed only +1.2% despite adjusted EPS of $6.38 versus $4.92 consensus because $860 million of favorable prior-period medical development accounts for roughly half of the adjusted EPS surprise; this is a low-quality beat under the TIF >30% one-time contribution rule.
The most investable positive is TSMC's demand duration, not the day's ADR reaction: Q3 revenue guidance of $44.6–45.8 billion implies another 12% sequential step-up, full-year USD revenue growth is now slightly above 40%, and HPC reached 66% of revenue. The cleanest tactical positive is Citizens, where sequential NII growth, fee growth, positive operating leverage and stable credit all moved together. The cleanest avoid is Wipro: IT-services revenue fell 1.2% sequentially, margin fell 120 basis points year over year, and next-quarter constant-currency guidance remains between -1.5% and +0.5%.
All ten names remain explicitly marked PROVISIONAL — CALL HIGHLIGHTS ONLY because the deterministic bundle retained call takeaways, not complete searchable Q&A. Commerce Bancshares had no call evidence at all. No final management-credibility delta is claimed until full transcripts are retained.
| Ticker | Action | Conviction | Closing move | One-line PM brief |
|---|---|---|---|---|
| [[TSM]] | ADD | Medium, transcript-capped | -2.3% | The market is fading capex intensity, but Q3's 12% sequential revenue step and >40% FY growth keep the AI foundry thesis structurally positive. |
| [[UNH]] | WAIT | Medium | +1.2% | The earnings floor improved, but favorable reserve development explains a material share of the beat; require clean MCR follow-through. |
| [[GE]] | HOLD | Medium | -4.1% | Orders, revenue and FCF are strong, but 130 bps of margin compression and ~45x guided EPS leave no room for execution slippage. |
| [[ABT]] | HOLD | Medium | +10.7% | The portfolio inflected positively, but the $0.78 GAAP-to-adjusted EPS gap and post-print rerating argue against chasing. |
| [[PLD]] | HOLD | Medium | +4.6% | Record leasing and a second guide raise confirm recovery; ~24x Core FFO and 4.7x leverage already capitalize much of it. |
| [[USB]] | ADD | Medium | +1.6% | NII, fee growth and operating leverage improved together at ~12x annualized Q2 EPS. |
| [[STT]] | HOLD | Low-medium | -0.5% | Flows, fee growth and operating leverage were strong, but the stock's rejection says the market had a higher bar or questions durability. |
| [[CFG]] | ADD ≤$70 | Medium | +4.6% | The synchronized NII/fee/credit improvement is real; use a pullback rather than chase the event-day move. |
| [[WIT]] | AVOID | Medium | +0.5% | Flat-to-negative forward growth plus falling margins is not an AI-services inflection. |
| [[CBSH]] | HOLD | Low, release-only | +2.1% | NIM expansion and a modest EPS beat help, but no transcript and offsetting securities items cap the conclusion. |
| Ticker | Reported result vs dated point hurdle | Forward evidence | What the stock priced |
|---|---|---|---|
| TSM | ADR EPS approximately $4.31 vs Nasdaq $3.87; revenue at top of prior guide | Q3 revenue $44.6–45.8B; FY growth slightly above 40%; capex $60–64B | Capex/depreciation risk outweighed the operating beat for one session |
| UNH | Adj. EPS $6.38 vs $4.92; revenue $112.0B vs $110.9B collector estimate | FY adj. EPS $19.50–20.00; MCR 88.1% ±25 bps | Investors discounted reserve-driven quality and demanded clean utilization evidence |
| GE | Adj. EPS $2.02 vs $1.86 | FY EPS $7.65–7.85; FCF $8.9–9.2B; high-teens revenue growth | Margin compression and valuation trumped the raised guide |
| ABT | Adj. EPS $1.31 vs $1.28; official sales $12.6B | FY adj. EPS raised to $5.45–5.60; 6.5–7.5% comparable sales guide reaffirmed | Product-cycle acceleration and portfolio normalization |
| PLD | Core FFO $1.63 vs $1.53 point hurdle | FY Core FFO raised to $6.22–6.30; cash same-store NOI guide 6.75–7.25% | Logistics recovery plus data-center optionality |
| USB | EPS $1.35 vs $1.29 | NII +7.5% YoY, fees +13.2%, 400 bps positive operating leverage | Clean earnings quality with contained credit |
| STT | EPS $3.65 vs $3.34 | Fee revenue +16%, NII +18%, net inflows $114B | Strong print was already expected or revenue definitions disappointed |
| CFG | EPS $1.30 vs $1.25 | NII +4.4% QoQ; fees +8%; NCO 37 bps | Higher NIM/earnings path with stable credit |
| WIT | ADR EPS comparison not reliable | Q2 CC revenue -1.5% to +0.5%; margin 16% in Q1 | Low expectations, but no fundamental inflection |
| CBSH | EPS $1.10 vs $1.045; revenue $487.3M vs $491.3M collector estimate | NIM 3.77%; fee revenue +$8M | Modest earnings resilience, not a major narrative break |
Point hurdles are from the Nasdaq earnings-calendar snapshot retained in the deterministic evidence JSON on 2026-07-16. Full consensus ranges and buy-side whispers were not available and are labeled not verifiable below.
Pre-print stack. Management's prior Q2 guide was $39.0–40.2 billion revenue, 65.5–67.5% gross margin and 56.5–58.5% operating margin. The dated Nasdaq EPS point hurdle was $3.87 per ADR; a consensus range and verified buy-side hurdle were not available. There is no TSM entry in the TIF Analytical Ledger, so the TIF threshold is not established. At $409.74, annualizing Q2 ADR EPS implies roughly 24x earnings, a bar that requires sustained 30%+ growth and controlled depreciation dilution.
| Metric | Prior guide / Street | Actual | Variance and rate of change | Classification |
|---|---|---|---|---|
| Revenue | $39.0–40.2B guide | $40.20B | Top of guide; +33.7% YoY; HPC +20% QoQ | STRUCTURAL POSITIVE |
| ADR EPS | $3.87 point hurdle | ~ $4.31 equivalent | ~11% above point hurdle; +77.4% YoY in NT$ per-share terms | STRUCTURAL POSITIVE |
| Gross margin | 65.5–67.5% | 67.7% | +120 bps vs midpoint | STRUCTURAL POSITIVE |
| Operating margin | 56.5–58.5% | 60.3% | +280 bps vs midpoint | STRUCTURAL POSITIVE |
| Q3 revenue | Buy-side hurdle not verifiable | $44.6–45.8B | +12% QoQ at midpoint | STRUCTURAL POSITIVE |
Release-only read. Demand and mix were stronger than the stock reaction suggests: advanced nodes were 77% of wafer revenue, HPC was 66% of total revenue, and N2 already contributed 3%. The three questions for the call were whether AI demand remained multi-year, whether overseas fabs would structurally dilute margins, and whether the capex step was customer-backed or speculative.
Call evidence and release-to-call delta. Retained call highlights answered the first question positively: management raised 2026 USD revenue growth to slightly above 40% and capex to $60–64 billion, explicitly tying it to multi-year AI/HPC demand. The information delta is mixed for the stock: demand duration improved, but depreciation and overseas-fab dilution risk also rose. Full Q&A, language comparison and answer-quality grading are blocked; management credibility remains UNCHANGED / UNRESOLVED, not upgraded.
Estimate bridge. FY1 revenue should rise mechanically with the >40% guide and Q3 midpoint of $45.2 billion. The EPS bridge is wafer volume × advanced-node mix × price – overseas-fab dilution – depreciation; Q2 margin upside supports FY1 EPS, while the $60–64 billion capex plan may limit FY2 margin expansion. Published FY1/FY2 post-print revisions were not available.
Thesis delta. Demand REINFORCED; pricing/mix IMPROVED; margin IMPROVED for FY1 but UNRESOLVED for FY2; competition UNCHANGED; capital allocation WEAKENED for near-term free-cash conversion but strategically REINFORCED; credibility UNRESOLVED; catalyst timing IMPROVED to Q3. Old narrative: AI demand is strong but peaking. New narrative: demand is broadening faster than supply, while the debate migrates from revenue durability to capital efficiency. Next proof: Q3 revenue at or above $44.6 billion and gross margin at or above 65%.
Business / estimate / stock delta. Business positive; FY1 estimates positive, FY2 margins less certain; the -2.3% stock move looks like a capex-duration de-rating rather than evidence of demand deterioration.
Action: ADD, medium conviction, transcript-capped. Add modestly, not maximum size. Confirmation is Q3 revenue ≥$44.6B with gross margin ≥65%. Falsification is Q3 revenue <$43.5B or gross margin <64% without a quantified temporary cause. Next catalyst: July monthly sales on August 10, then Q3 earnings in October. (TSMC Q2 results; source date 2026-07-16) #sellside
Pre-print stack. The dated EPS point hurdle was $4.92 and the collector's revenue estimate was $110.9 billion; ranges and a buy-side hurdle were not verifiable. There is no UNH Ledger entry. At $423.38, the new $19.50–20.00 adjusted EPS guide implies 21.4x midpoint earnings, requiring the medical-cost remediation to persist.
| Metric | Street / prior | Actual / guide | Variance and quality | Classification |
|---|---|---|---|---|
| Adjusted EPS | $4.92 | $6.38 | +29.8%; ~$860M favorable prior-period medical development explains roughly half the beat | ACCOUNTING / LOW-QUALITY BEAT |
| Revenue | $110.9B | $112.0B | +~1.0%; approximately flat YoY | NOISE / IMMATERIAL |
| Operating earnings | n/v | $8.0B | +55% YoY | STRUCTURAL POSITIVE, subject to reserve quality |
| Medical care ratio | n/v | 86.7% | Includes favorable prior-period development | TIMING POSITIVE |
| FY adjusted EPS | prior range not retained | $19.50–20.00 | Raised/refreshed | STRUCTURAL POSITIVE if MCR holds |
EPS quality gate. The $1.46 EPS surprise versus the point estimate is not clean. Applying a rough tax/share conversion to $860 million of favorable prior-period development suggests about $0.7–0.8 per share, more than 30% of the beat and likely near half. The print therefore fails the TIF quality gate even though cash flow was strong at $11.1 billion, or 1.9x net income.
Release-only read. Remediation is working, cash generation is real, and leverage improved by 170 bps sequentially to 41.2% debt-to-capital. Questions for the call: how much of the MCR improvement is repeatable, what 2026 pricing/utilization assumptions support the guide, and whether Optum Health's earnings floor is operational or reserve-driven.
Call evidence and release-to-call delta. Highlights supplied an 88.1% ±25 bps FY MCR guide, at least $12 billion of UnitedHealthcare operating earnings and at least $2.2 billion for Optum Health. That improves visibility but does not resolve reserve quality. Full Q&A and directness grading were not retained, so credibility remains UNRESOLVED after the prior medical-cost forecasting failure.
Estimate bridge. FY1 adjusted EPS is anchored at $19.50–20.00. Algebra: premium pricing + membership mix – medical utilization – pharmacy trend – operating expense + buybacks. FY2 requires MCR normalization without another reserve release; no clean FY2 consensus or published revisions were available. The $5 billion-plus buyback target supports EPS but must be separated from operating improvement.
Thesis delta. Demand/membership UNCHANGED; pricing IMPROVED; medical margin IMPROVED BUT UNRESOLVED; Optum competition UNCHANGED; balance sheet IMPROVED; credibility UNRESOLVED; catalyst timing IMPROVED to the next utilization update. Old narrative: UNH cannot forecast medical cost. New narrative: remediation has created a recoverable earnings floor, but the quality of the first clean quarter is reserve-assisted. Next proof: MCR within 87.85–88.35% and adjusted EPS at least $19.50 for FY26.
Business / estimate / stock delta. Business modestly positive; FY1 estimate positive; the +1.2% close after an initially stronger reaction says the stock correctly discounted low-quality upside.
Action: WAIT, medium conviction. Do not chase. Upgrade to ADD if the next quarter delivers MCR ≤88.35% without material favorable prior-period development. Falsification is MCR >88.6% or FY adjusted EPS guidance below $19.50. Next catalyst: Q3 results in October. (UnitedHealth Q2 release; 2026-07-16) #sellside
Pre-print stack. Nasdaq's dated EPS point hurdle was $1.86; consensus range and verified buy-side hurdle were unavailable. There is no GE Ledger entry. At $345.73, the new $7.65–7.85 EPS guide implies ~44.6x midpoint earnings—an exceptionally high bar requiring services growth and margin conversion with little interruption.
| Metric | Street / prior | Actual / guide | Variance | Classification |
|---|---|---|---|---|
| Adjusted EPS | $1.86 | $2.02 | +8.6%, +22% YoY | STRUCTURAL POSITIVE |
| Revenue | consensus definition conflicted | +24% YoY | CES +27%, DPT +16% | STRUCTURAL POSITIVE |
| Operating profit | n/v | $2.7B | +18% YoY | STRUCTURAL POSITIVE |
| Operating margin | n/v | 21.7% | -130 bps YoY | STRUCTURAL NEGATIVE |
| FCF | n/v | $3.0B | +43%; >140% conversion | STRUCTURAL POSITIVE |
| FY guide | prior values not retained | EPS $7.65–7.85; FCF $8.9–9.2B | Raised | STRUCTURAL POSITIVE |
Release-only read. Services and output are compounding: orders +17%, total engine deliveries +31%, LEAP +41%, and commercial-services revenue +32% in the first half. The problem is conversion—revenue grew faster than profit and margin compressed. Call questions were whether equipment mix alone explains the pressure, when services growth restores margin, and whether supplier investment absorbs more cash.
Call evidence and release-to-call delta. The call highlights reinforced backlog visibility (~$170 billion commercial services) and raised the full-year guide, but did not supply retained Q&A on the 130-bp margin decline. The call therefore improves the revenue and cash thesis but leaves the valuation-critical margin bridge unresolved. Credibility is UNCHANGED pending a quantified recovery timetable.
Estimate bridge. FY1 is now bounded by $7.65–7.85 EPS and $8.9–9.2B FCF. The bridge is shop visits × material/price per visit + engine deliveries + defense volume – equipment mix dilution – supplier/capacity investment. FY2 upside requires margin recovery; no post-print FY2 consensus was retained.
Thesis delta. Demand REINFORCED; pricing/services mix IMPROVED; margins WEAKENED; competition UNCHANGED; balance sheet/capital return IMPROVED via cash; credibility UNRESOLVED; catalyst timing UNCHANGED. Old narrative: backlog converts into simultaneous high-teens growth and margin expansion. New narrative: backlog conversion is strong, but equipment/output acceleration temporarily dilutes the premium-margin thesis. Next proof: margin stabilizes while FCF remains inside guide.
Business / estimate / stock delta. Business positive, FY1 estimates positive, stock less attractive because the multiple already demanded a cleaner margin profile. The -4.1% reaction is reasonable, not obviously an overreaction.
Action: HOLD, medium conviction. Confirmation is FY FCF ≥$8.9B and second-half operating margin no worse than 21.7%. Falsification is full-year FCF below $8.9B or another >100-bp YoY margin decline with no dated recovery bridge. Next catalyst: Q3 earnings in October. (GE Q2 event, release and transcript hub; 2026-07-16) #sellside
Pre-print stack. Nasdaq's adjusted EPS point hurdle was $1.28. The collector's revenue field conflicts with Abbott's official $12.6 billion sales figure and is quarantined; revenue consensus is not verifiable. Prior adjusted EPS guidance was $5.38–5.58. There is no ABT Ledger entry. At $98.83, the new $5.45–5.60 range implies ~17.9x midpoint adjusted EPS after the 10.7% rally.
| Metric | Street / prior | Actual / guide | Variance | Classification |
|---|---|---|---|---|
| Adjusted EPS | $1.28 | $1.31 | +2.6% | STRUCTURAL POSITIVE, small magnitude |
| GAAP EPS | n/v | $0.53 | $0.78 below adjusted EPS | ACCOUNTING / QUALITY WATCH |
| Sales | revenue consensus blocked | $12.6B | +13.0% reported; +4.8% comparable | STRUCTURAL POSITIVE |
| Medical Devices | n/v | +8.5% comparable | EP +13.4%; CGM >$2B, +9.5% | STRUCTURAL POSITIVE |
| FY adjusted EPS | $5.38–5.58 prior | $5.45–5.60 | midpoint +$0.045 | STRUCTURAL POSITIVE |
Release-only read. Multiple growth legs improved simultaneously: electrophysiology, rhythm management, heart failure, cancer diagnostics and established pharmaceuticals. The three questions were whether second-half acceleration is product-led rather than acquisition/FX-led, whether the GAAP adjustments recur, and whether Nutrition is truly stabilizing.
Call evidence and release-to-call delta. Management pointed to Volt PFA, TactiFlex Duo, Libre Duo and other launches as second-half catalysts, while reaffirming 6.5–7.5% comparable sales growth. That adds a dated mechanism to the guide raise. The missing Q&A prevents grading pushback on Nutrition, CGM competition and the $0.78 adjusted-to-GAAP bridge.
Estimate bridge. FY1 adjusted EPS moves to $5.45–5.60. Algebra: comparable volume × device/diagnostics mix × gross-margin expansion – launch spend – acquisition amortization/restructuring. FY2 rises only if new devices sustain double-digit growth and the GAAP adjustment burden falls. Published revisions were unavailable.
Thesis delta. Demand IMPROVED; pricing/mix IMPROVED; margins IMPROVED on an adjusted basis but UNRESOLVED on GAAP; competition IMPROVED in EP/PFA; capital allocation UNCHANGED; credibility IMPROVED provisionally; catalyst timing IMPROVED. Old narrative: mature nutrition/diagnostics dilute device growth. New narrative: the device and diagnostics product cycle can reaccelerate the whole portfolio. Next proof: H2 comparable sales ≥6.5% and continued low-double-digit EP growth.
Business / estimate / stock delta. Business positive; FY1 estimates modestly positive; stock attractiveness is unchanged to slightly lower after the 10.7% rerating.
Action: HOLD, medium conviction. Do not chase. Confirmation is H2 comparable growth ≥6.5% with Medical Devices ≥9%. Falsification is comparable growth below 6% or FY EPS midpoint below $5.525. Next catalyst: Q3 earnings in October and U.S. product-launch milestones. (Abbott Q2 call summary and official metrics; 2026-07-16) #sellside
Pre-print stack. The calendar point hurdle was $1.53, best interpreted as Core FFO rather than GAAP EPS. Prior FY Core FFO guidance was $6.07–6.23; occupancy 95.00–95.75%; cash same-store NOI 6.25–7.00%. No PLD Ledger entry exists. At $150.06, the new $6.22–6.30 Core FFO range is ~24.0x midpoint. Debt/adjusted EBITDA is 4.7x, so leverage and EV/EBITDA—not P/E—must lead the risk assessment.
| Metric | Street / prior | Actual / guide | Variance | Classification |
|---|---|---|---|---|
| Core FFO/share | $1.53 point hurdle | $1.63; $1.60 ex promote | +6.5% / +4.6% | STRUCTURAL POSITIVE |
| Period-end occupancy | prior guide 95.00–95.75% avg | 95.5% | +20 bps QoQ | STRUCTURAL POSITIVE |
| Cash same-store NOI | 6.25–7.00% prior FY guide | 8.5% Q2; 6.75–7.25% new FY guide | floor +50 bps | STRUCTURAL POSITIVE |
| Rent change | n/v | 36.9% net effective; 22.3% cash | Embedded earnings visibility | STRUCTURAL POSITIVE |
| FY Core FFO | $6.07–6.23 | $6.22–6.30 | midpoint +$0.11 | STRUCTURAL POSITIVE |
Release-only read. Record leasing (>67 million square feet), improving occupancy and a second guide raise confirm that the logistics trough is ending. The 5.8 GW data-center power pipeline adds optionality. Questions for the call were conversion timing, return on the $4.5–5.5B development-start guide, and whether 4.7x leverage rises before cash generation catches up.
Call evidence and release-to-call delta. Highlights confirmed $2.1B of year-to-date data-center development, 4.7x leverage, 3.3% average debt cost and 7.9-year average maturity. The call therefore reduces near-term refinancing risk but does not resolve capital-intensity or SEGRO transaction risk. Full Q&A was not retained.
Estimate bridge. FY1 Core FFO rises to $6.22–6.30. Algebra: occupancy × rent roll-up + promote income + development stabilization – interest expense – incremental G&A. FY2 depends on converting the data-center pipeline and logistics starts at attractive spreads. Each +100 bps on the debt stack would be material, but the mostly fixed, long-duration debt delays the cash impact; exact variable-rate debt was unavailable.
Thesis delta. Demand IMPROVED; pricing REINFORCED; margins/NOI IMPROVED; competition UNCHANGED; balance sheet UNCHANGED with elevated but bounded leverage; credibility IMPROVED provisionally; catalyst timing IMPROVED. Old narrative: leasing recovery is too slow to offset rates. New narrative: occupancy and rent roll-up are inflecting while data centers create a second growth engine. Next proof: average occupancy ≥95.25% and cash same-store NOI ≥6.75%.
Business / estimate / stock delta. Business positive; FY1 estimates positive; stock fair rather than cheap after +4.6% at 24x FFO.
Action: HOLD, medium conviction. Confirmation is occupancy ≥95.25%, cash same-store NOI ≥6.75% and leverage ≤4.8x. Falsification is occupancy <94.75%, leverage >5.0x or development yields falling below funding cost. Next catalyst: Q3 earnings and data-center start/conversion updates. (Prologis Q2 release; 2026-07-16) #sellside
Pre-print stack. Dated EPS point hurdle was $1.29; ranges and buy-side hurdle were unavailable. The TIF bank note classifies USB as a super-regional but contains no actionable prior call; there is no Ledger entry. At $64.01, annualized Q2 EPS implies ~11.9x earnings.
| Metric | Street / prior | Actual | Variance / rate | Classification |
|---|---|---|---|---|
| EPS | $1.285 | $1.35 | +5.1%; +22% YoY | STRUCTURAL POSITIVE |
| Net revenue | n/v | $7.7B | +10.1% YoY | STRUCTURAL POSITIVE |
| NII / NIM | n/v | $4.4B / 2.79% | NII +7.5% YoY | STRUCTURAL POSITIVE |
| Fee revenue | n/v | 44% of revenue | +13.2% YoY | STRUCTURAL POSITIVE |
| Operating leverage | n/v | +400 bps | Revenue growth well above expense growth | STRUCTURAL POSITIVE |
| Credit / capital | n/v | NPA 0.33%; CET1 10.8% | NPA -5 bps | STRUCTURAL POSITIVE |
Release-only read. The beat is operating, not below-the-line: NII, fees and efficiency all improved. BTIG contributed $98M in its first month, so acquisition contribution must be separated from organic growth. Questions for the call were the pro-forma expense run-rate, deposit beta and whether loan growth at 7.1% YoY requires weaker underwriting.
Call evidence and release-to-call delta. Highlights showed record consumer deposits, payments revenue +5.7%, ROTCE 18.7% and efficiency at 57.1%. This improves the quality read, but full Q&A on deposits, credit and BTIG integration was not retained. Credibility is provisionally IMPROVED.
Estimate bridge. No FY1/FY2 consensus was available. Annualized Q2 EPS is $5.40 before seasonality. The bridge is average earning assets × NIM + payments/capital-markets fees – expenses – provision – share count. FY2 improves if NIM holds and BTIG revenue scales faster than expenses.
Thesis delta. Loan demand IMPROVED; pricing/NIM IMPROVED; operating leverage IMPROVED; competitive position IMPROVED via payments and BTIG; capital UNCHANGED/STRONG; credibility IMPROVED provisionally; catalyst timing UNCHANGED. Old narrative: deposit costs cap super-regional upside. New narrative: diversified fees and positive operating leverage can offset deposit pressure. Next proof: NIM ≥2.79% and positive operating leverage next quarter.
Business / estimate / stock delta. Business positive; estimates positive; +1.6% looks like underreaction if credit remains contained.
Action: ADD, medium conviction. Confirmation is NIM ≥2.79%, efficiency ≤58% and NPA ≤0.40%. Falsification is CET1 <10.5%, NPA >0.50% or negative operating leverage. Next catalyst: Q3 earnings in October. (U.S. Bancorp Q2 release hub; 2026-07-16) #sellside
Pre-print stack. Dated EPS point hurdle was $3.34. The collector's $3.80B revenue field conflicts with call-reported total revenue of approximately $4.0B, so a revenue beat/miss is not stated. The TIF bank note classifies STT as a custody bank and expected sequential NII pressure, but contains no position call; no Ledger entry exists. At $185.66, annualized Q2 EPS implies ~12.7x.
| Metric | Street / prior | Actual | Variance / rate | Classification |
|---|---|---|---|---|
| EPS | $3.34 | $3.65 | +9.2%; +44% YoY | STRUCTURAL POSITIVE |
| Total revenue | consensus definition blocked | ~$4.0B | +17% YoY | STRUCTURAL POSITIVE |
| Fee revenue | n/v | $3.2B | +16% YoY | STRUCTURAL POSITIVE |
| NII / NIM | sequential pressure expected in TIF note | $860M / 1.13% | +18% YoY; NIM +17 bps | STRUCTURAL POSITIVE |
| Pretax margin | n/v | 34% | +470 bps YoY | STRUCTURAL POSITIVE |
| Net inflows | n/v | $114B | AUM +23% YoY to $6.3T | STRUCTURAL POSITIVE |
Release-only read. State Street beat the specific TIF sector expectation of sequential NII pressure and delivered broad fee growth. The questions were how much came from market beta versus organic flows, whether 10% expense growth reaccelerates, and whether ETF pricing pressure offsets AUM gains.
Call evidence and release-to-call delta. Highlights showed AUC/A $57.9T (+18%), AUM $6.3T (+23%), management fees +29%, FX trading +27% and servicing +13%, but software revenue -14%. The breadth supports a real operating improvement. The -0.5% stock reaction implies the hurdle was higher, revenue conventions disappointed, or investors doubt market-sensitive durability. Full Q&A was not retained.
Estimate bridge. Annualized Q2 EPS is $14.60 before seasonality. Algebra: AUC/A × servicing yield + AUM × fee rate + trading volumes + NII – expenses. FY2 depends on organic flows and expense discipline more than market beta. Full consensus estimates and revisions were unavailable.
Thesis delta. Demand/flows IMPROVED; pricing UNRESOLVED; margins IMPROVED; competition UNCHANGED; capital allocation IMPROVED with a 10% dividend increase; credibility IMPROVED provisionally; catalyst timing UNCHANGED. Old narrative: custody-bank NII rolls over and fee pressure persists. New narrative: flows, NII and operating leverage can rise together, but investors need proof it is not purely market beta.
Business / estimate / stock delta. Business and estimates positive; stock reaction negative/flat, making it interesting but not actionable without Q&A and revenue reconciliation.
Action: HOLD, low-medium conviction. Confirmation is positive net flows, fee growth above expense growth and NII ≥$850M. Falsification is net outflows plus NII below $800M or expenses growing faster than fee revenue. Next catalyst: Q3 earnings. (State Street Q2 release; 2026-07-16) #sellside
Pre-print stack. Dated EPS point hurdle was $1.25; the full range and buy-side hurdle were unavailable. The TIF note classifies CFG as a super-regional but contains no call. There is no Ledger entry. At $74.40, annualized Q2 EPS implies ~14.3x, higher than USB and therefore requiring superior growth.
| Metric | Street / prior | Actual | Variance / rate | Classification |
|---|---|---|---|---|
| EPS | $1.25 | $1.30 | +4.4%; +15% QoQ; +41% YoY | STRUCTURAL POSITIVE |
| NII | n/v | amount not retained | +4.4% QoQ; +14% YoY | STRUCTURAL POSITIVE |
| Fees | n/v | amount not retained | +8% QoQ; +9% YoY | STRUCTURAL POSITIVE |
| Operating leverage | n/v | +4% QoQ; +6.4% YoY | Broad-based | STRUCTURAL POSITIVE |
| Net charge-offs | n/v | 37 bps | -2 bps QoQ | STRUCTURAL POSITIVE |
| CET1 | n/v | 10.4% | Supports capital return | STRUCTURAL POSITIVE |
Release-only read. This is the cleanest bank combination of the morning: NII, fees, operating leverage and credit improved together. Questions were whether private-bank growth is deposit-accretive, whether capital-markets fees are repeatable, and whether loan growth changes the credit mix.
Call evidence and release-to-call delta. Highlights showed private-bank deposits of $17.8B, loans of $9.7B, capital-markets fees +46% YoY, wealth fees +16%, and $422M returned to shareholders. That reinforces franchise mix and capital return. Full Q&A on credit and NIM sensitivity was not retained, so the call cannot fully validate durability.
Estimate bridge. Annualized Q2 EPS is $5.20. Algebra: loan growth × NIM + capital-markets/wealth fees – expenses – provision – shares. FY2 upside requires private-bank and fee growth without NCO normalization above 40 bps. Published revisions were unavailable.
Thesis delta. Demand IMPROVED; NIM/pricing IMPROVED; margins IMPROVED; competitive position IMPROVED; capital UNCHANGED/HEALTHY; credibility IMPROVED provisionally; catalyst timing UNCHANGED. Old narrative: regional-bank upside is mostly rate beta. New narrative: Citizens has an idiosyncratic private-bank and fee-growth engine. Next proof: sequential NII growth ≥2% and NCO ≤40 bps.
Business / estimate / stock delta. Business positive; estimates positive; +4.6% is justified and reduces near-term upside.
Action: ADD at $70 or below, medium conviction. Confirmation is NII growth ≥2% QoQ, fee growth ≥5% YoY and NCO ≤40 bps. Falsification is NCO >50 bps, CET1 <10.0% or NIM reversal sufficient to make NII negative sequentially. Next catalyst: Q3 earnings. (Citizens Q2 release; 2026-07-16) #sellside
Pre-print stack. Nasdaq's ADR EPS point hurdle was $0.03–0.035, but the collector did not retain a reliable ADR-adjusted actual; do not force a comparison. Prior Q1 IT-services constant-currency guide from the April release was not retained in the evidence bundle. There is no WIT Ledger entry. At $1.85, valuation cannot be reliably bridged without an ADR share-ratio and FY consensus snapshot.
| Metric | Prior / Street | Actual / guide | Rate | Classification |
|---|---|---|---|---|
| IT-services revenue | prior guide not retained | $2.61B | +0.9% YoY CC; -1.2% QoQ | STRUCTURAL NEGATIVE |
| IT-services margin | n/v | 16.0% | -120 bps YoY | STRUCTURAL NEGATIVE |
| Net income | n/v | INR33.6B | +0.6% YoY | NOISE / IMMATERIAL |
| Orders / large deals | n/v | $3.4B / $1.6B | 13 large deals | TIMING POSITIVE until revenue converts |
| Q2 revenue guide | buy-side hurdle n/v | $2.574–2.627B | -1.5% to +0.5% QoQ CC | STRUCTURAL NEGATIVE |
Release-only read. Large deals are not converting fast enough to offset revenue pressure and investment. Americas 2 fell 7.3% YoY, Energy/Manufacturing/Resources fell 8.9%, and salary increases, deal ramp costs and AI investment compressed margin. Questions were when bookings become revenue, whether AI cannibalizes traditional services faster than it adds new work, and when margin returns above 17%.
Call evidence and release-to-call delta. Retained highlights confirmed the negative guide and mix weakness; APMEA +13.5% and Europe +6% are insufficient to offset the weak Americas 2 and EMR clusters. Full Q&A and wording comparison were not retained. Credibility is UNCHANGED/WEAKENED because guidance still lacks a clear growth inflection.
Estimate bridge. Q2 revenue is bounded at $2.574–2.627B. Algebra: large-deal conversion + discretionary demand + pricing – ramp leakage – wages – AI investment. FY1 estimates should be flat-to-down until constant-currency growth turns positive; FY2 remains unmodelable without conversion cadence.
Thesis delta. Demand WEAKENED; pricing/mix WEAKENED; margins WEAKENED; competitive position UNRESOLVED; capital allocation UNCHANGED; credibility WEAKENED; catalyst timing DELAYED. Old narrative: AI and large-deal bookings drive a services rebound. New narrative: AI investment is currently a margin cost while legacy demand remains soft. Next proof: >2% sequential CC growth and margin ≥17%.
Business / estimate / stock delta. Business negative, estimates negative, stock's +0.5% move is expectation relief rather than thesis improvement.
Action: AVOID, medium conviction. Upgrade trigger is two consecutive quarters of >2% sequential constant-currency growth with margin ≥17%. Further falsification of any recovery case is Q2 below the low end of $2.574B or margin <15.5%. Next catalyst: Q2 FY27 results in October. (Wipro results announcement and webcast details; 2026-07-16) #sellside
Pre-print stack. Dated EPS point hurdle was $1.045 and collector revenue estimate $491.3M. No buy-side hurdle, consensus range, prior guide or TIF Ledger threshold was available. At $59.40, annualized Q2 EPS implies ~13.5x.
| Metric | Street / prior | Actual | Variance / rate | Classification |
|---|---|---|---|---|
| EPS | $1.045 | $1.10 | +5.3%; +1% YoY; +14.6% QoQ | STRUCTURAL POSITIVE |
| Revenue | $491.3M collector estimate | $487.3M collector actual | -0.8% | NOISE / IMMATERIAL pending primary reconciliation |
| Net income | n/v | $159.8M | +4.8% YoY; +12.9% QoQ | STRUCTURAL POSITIVE |
| NIM | n/v | 3.77% | expanded | STRUCTURAL POSITIVE |
| Fee revenue | n/v | +$8.0M | trust, card and deposit fees | STRUCTURAL POSITIVE |
| Securities items | n/v | +$105.4M Visa gain; -$97.7M repositioning loss | largely offset | ACCOUNTING / BELOW-THE-LINE |
Release-only read. Core earnings appear modestly better, led by NIM and fees, while the Visa gain and securities loss mostly offset. Three call questions: normalized NIM after repositioning, deposit pricing, and credit migration. No conference-call evidence was retained, so there is no post-call read, Q&A pressure map or credibility delta.
Estimate bridge. Annualized Q2 EPS is $4.40. Algebra: earning assets × NIM + trust/card/deposit fees – expenses – normalized credit – securities noise. FY1 can rise modestly if NIM 3.77% persists; FY2 remains blocked without a funding-cost and loan-growth guide.
Thesis delta. Demand UNRESOLVED; pricing/NIM IMPROVED; margins IMPROVED; competition UNCHANGED; capital allocation UNRESOLVED; credibility UNRESOLVED; catalyst timing UNCHANGED. Old narrative: high-quality Midwest banking but limited growth. New narrative: securities repositioning and NIM expansion can create an earnings floor, but the magnitude is not yet proven. Next proof: NIM ≥3.75% with positive core fee growth.
Business / estimate / stock delta. Business modestly positive; estimate modestly positive; +2.1% looks proportionate.
Action: HOLD, low conviction. Confirmation is NIM ≥3.75% and fee revenue growth >3% with no credit deterioration. Falsification is NIM <3.60% or a material rise in charge-offs/provisions. Queue for PM transcript catch-up. (Commerce Q2 earnings exhibit; release date 2026-07-16) #sellside
The deterministic PM collector found zero qualifying July 15 AMC companies above $2B. Its unsupplied-time watch list consisted of the same July 15 names already covered in the prior AM report, not confirmed AMC releases. No company is carried into today's catch-up. This is a valid empty set, not a skipped section.
| Ticker | Nasdaq EPS point | Decision metric | Beat / miss definition |
|---|---|---|---|
| [[NFLX]] | $0.79 | Advertising revenue/run-rate, engagement and operating-margin guide | Beat requires ad monetization and margin guide to rise together; subscriber/engagement strength without margin conversion is insufficient. |
| [[AA]] | $2.33 | Realized aluminum/alumina price, shipments, EBITDA and cash conversion | Beat requires EBITDA/cash upside not solely spot-price mark-to-market; miss is higher costs or lower shipment guidance. |
| [[VIST]] | $3.15 | Production growth, lifting cost and realized pricing | Beat requires volume growth with stable unit cost; miss is capex/cost inflation absorbing production upside. |
| [[FNB]] | $0.42 | NII/NIM, deposit beta and criticized assets | Beat requires NIM stability plus contained credit; EPS from reserve release alone fails quality. |
| [[INDB]] | $1.77 | Core NIM, deposit cost and merger/integration expense | Beat requires organic NII after adjustments; miss is funding pressure or rising provision. |
| [[CNS]] | not available | Net flows, AUM mix and fee rate | Beat requires positive organic flows, not market-beta AUM alone. |
| [[SFNC]] | $0.53 | NIM, loan growth and credit normalization | Beat requires positive operating leverage with stable charge-offs. |
FFIN, BANF and WAFD were listed with unspecified reporting times and are not treated as confirmed AMC names.
| Ticker | Nasdaq EPS point | Decision metric | Beat / miss definition |
|---|---|---|---|
| [[TRV]] | $5.16 | Underlying combined ratio, catastrophe load and renewal premium change | Beat requires underlying margin and pricing to improve; catastrophe timing alone is noise. |
| [[TFC]] | $1.08 | NII/NIM, deposit beta, fee growth and credit | Beat requires positive NII revision without reserve release; miss is renewed deposit-cost pressure. |
| [[FITB]] | $0.98 | NIM, payments/wealth fees and criticized assets | Beat requires fee breadth plus stable credit; headline EPS without NIM support is low quality. |
| [[RF]] | $0.64 | NII guide, deposit costs and net charge-offs | Beat requires stable/rising NIM and NCO containment. |
| [[ALV]] | $2.34 | Organic sales versus light-vehicle production, margin and FCF | Beat requires content-per-vehicle and margin gains, not FX; miss is production underperformance or cost leakage. |
No existing Analytical Ledger catalyst for these ten tickers arrived, so the Ledger was not modified. The TIF bank note supplied sector classification for USB/STT/CFG but no actionable prior call to close.
/Users/max/morningsignal-research/state/earnings/earnings_context_2026-07-16_AM.json (generated 2026-07-16 22:18 ET; 10 qualifying companies; actual-result evidence 10/10; call evidence flag 9/10)./Users/max/morningsignal-research/state/earnings/earnings_context_2026-07-15_PM.json (0 qualifying PM companies)./Users/max/morningsignal-research/state/earnings/earnings_context_2026-07-17_AM.json (calendar only; stale actual_result flags ignored).not verifiable.Primary company sources are linked in each company section. No fabricated transcript text is present.